SCREENING PROGRAM Sample Clauses

SCREENING PROGRAM. The parties agree that the first Target shall be TGF beta receptor Type I. Upon designation of any additional Target by CUSTOMER, NeoGenesis will have [*] to agree to conduct the control and follow up control experiments of para. 2 of ATTACHMENT A with that Target or to reject (because of its unavailability) the Target. Upon such agreement, CUSTOMER shall within [*] deliver all necessary reagents with respect to such Target to NeoGenesis. NeoGenesis shall within [*] of receipt of such reagents conduct the control and follow-up experiments of para. 2 of ATTACHMENT A with respect to the Target. It will also establish an SOP as provided under that paragraph. The Program for a given Target will remain in effect for a period of [*] from the time of transfer of reagents by CUSTOMER to NeoGenesis, with an option by CUSTOMER to renew the Program for such Target for an additional [*] period on terms and conditions, including level of support, that are mutually agreeable. CUSTOMER shall notify NeoGenesis whether CUSTOMER wishes to extend the Program for a given Target for an additional [*], no later than [*] prior to termination of the initial term. NeoGenesis will apply its ALIS method to screen the NeoMorph Screening Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. evaluation and development. Alternatively, NeoGenesis shall apply ALIS screening of libraries provided by CUSTOMER as described in ATTACHMENT A. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall conduct the screening and deliver a Final Target Report as described in ATTACHMENT A, but in any event within [*] following the date that the applicable Target is delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
Sample 1See All (6)
AutoNDA by SimpleDocs
SCREENING PROGRAM. 13 3.1 Screening Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.1 Screening by Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.1.2
Sample 1Sample 2Sample 3
SCREENING PROGRAM. NeoGenesis will apply use its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. NeoGenesis shall commence the Program following the date the Targets are delivered to NeoGenesis and shall complete the Program within [*] following the date that the Targets are delivered to NeoGenesis, unless the parties agree in writing to extend the period for performance of the Program (the SCREENING PERIOD).
Sample 1Sample 2
SCREENING PROGRAM. (a) NeoGenesis will apply its ALIS method to screen the NeoMorph Library for activity with respect to each Target for purposes of identifying potentially useful chemical compounds for further evaluation and development. Screening will be performed pursuant to the screening protocol for the Program set forth in ATTACHMENT A. With respect to each Target delivered by OGS, NeoGenesis shall initiate its screening obligations as more particularly set out in the Program within [*] following the date of receipt of such Target and complete such screening obligations within [*] following the date it commences its screening obligations with respect to such Target, unless the parties agree in writing to extend the period for performance and except as otherwise provided in Section 2.1(a)(ii) (such period, the SCREENING PERIOD).
Sample 1Sample 2
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE B. Extension Assay *** *** FTE C. Neurotoxicity *** *** FTE D. Specificity *** *** FTE PPI will make available *** FTE's to the Screening Program immediately following the Effective Date. These FTE's will either be new hires or redeployments of existing personnel. PPI anticipates that it will be evaluating BI compounds in assays A-D within 6 weeks of first receiving compounds from BI. All Applicable data will be supplied to BI in PC compatible form (e.g. ASCI II or Excel files). All BI compounds will be handled or disposed of in accordance with BI's written instructions.
Sample 1Sample 2
SCREENING PROGRAM. The Program to be performed by NeoGenesis with respect to the Targets will screen compounds contained in the NeoGenesis NeoMorph Screening Library as updated from time to time by NeoGenesis (collectively, such compounds are the Compounds).
Sample 1
SCREENING PROGRAM. During the Screening Term, PPI will employ exclusively assays A-D as described below to screen for A(beta) peptide polymerization inhibition activity for 50,000 compounds selected and supplied by BI. *** Depending on activity levels seen in Assay A, PPI may require additional material for Assays B-D and subsequent in vivo assays. PPI will deliver to BI SAR data on existing PPI Compounds within 6 weeks of the Effective Date. BI will deliver to PPI at least 13,000, 25,000, 37,500, and 50,000 compounds within 2.0, 5.0, 12.0, and 16.0 months respectively, of the Effective Date and PPI anticipates, barring any unforeseen technical issues, screening 25,000 compounds in its Nucleation Assay within 12 months and 50,000 compounds in its Nucleation Assay within 24 months of the Effective Date. Compounds jointly designated will be further screened in secondary assays described below. Assay Functional Measurement Manpower ----- ---------------------- -------- A. Nucleation Assay *** *** FTE
Sample 1
AutoNDA by SimpleDocs
SCREENING PROGRAM 
Sample 1Sample 2Sample 3See All (4)

Related to SCREENING PROGRAM

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Plan As defined in Section 3.2(a).

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

Time is Money Join Law Insider Premium to draft better contracts faster.